Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Harry Ehrlich who wrote (1182)	3/2/1998 10:04:00 PM
From: unregmarket	Read Replies (1) \| Respond to of 2173

Harry and All: Isn't it also possible that the J&J fellas owning a shitload of AMLN cannot justify J&J's corporate $$$ in AMLN for the QUICKEST value, but they are happy as a lark to hold their personal shares - maybe even add - knowing that AMLN is successful in Phase III so far? A 1 - 2 year personal investment? Who knows, maybe J&J is dealing with AMLN to pull out while setting up other financing, and the AMLN staff reductions are due to more rapid successes at this point - no need to carry all the R&D employees forward. Stranger things have happened. Rick M.

To: Harry Ehrlich who wrote (1182)	3/2/1998 10:04:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 2173

Harry, Contrary to posts on this board, I'm not sure that everyone knew of JNJ's decision last week. I don't think that those who bought large blocks at $5 are very happy tonight. The bid and ask will begin to move at 8:00 AM and AMLN will open at 9:30. I suspect that the price will be sliced in half and I don't expect a significant recovery until there is some indication that the drug is approvable. I thought that the last set of Type I data was borderline and Type II data was not approvable. I'm not convinced that the new trials will show a marked improvement, and the JNJ decision will shake the confidence of most investors. AMLN is still a company heavily dependent on Amylin (and derivatives) and until they can show that they have an approval drug for a reasonable market, buyers will be in very short supply.